Loh L C, Lim B K, Raman S, Vijayasingham P, Mohd Yusuf S
IMU Lung Research, International Medical University, Kuala Lumpur, Malaysia.
Med J Malaysia. 2008 Aug;63(3):188-92.
Budesonide/Formoterol (Symbicort) combination therapy as both maintenance and reliever treatment (SMART) is a novel approach in asthma management. We examined its 'real-life effectiveness' in treating Malaysian patients with moderate-to-severe asthma in whom despite on combined inhaled corticosteroids and long-acting beta2-agonist, were still inadequately controlled. In a retrospective study, 22 eligible adult patients on SMART [mean (range) age: 49 (36-65) years; FEV1: 41 (21-74)% predicted] were identified from medical records of an urban-based university hospital chest clinic, and their clinical outcomes studied at three months. Another 16 patients [50 (14-66) years; 48 (20-91)% predicted] of similar severity and treatment (i.e. Symbicort maintenance treatment plus short-acting beta2-agonist as reliever), but not on SMART, were used as comparator over the same assessment period. In addition, the patients were separately interviewed with standard questionnaire on their satisfaction and compliance to the SMART approach. In SMART group, rescue treatment requirement (p<0.001) and FEV1 [median difference = 2.5%, p=0.015; mean difference: 90 ml, p=0.013] showed significant improvement while in comparator, there was significant improvement only in the requirement for rescue treatment (p=0.023). Hospital admission rates were significantly reduced in SMART group compared to the other (p=0.039), but not in emergency treatment. Five patients asked to discontinue SMART while all others were satisfied, compliant and perceived improvement of their asthma with SMART. The maximum daily doses of inhaled budesonide and formoterol were 1400 microg and 31.5 microg respectively. Our preliminary findings suggest that SMART approach can be attempted as an effective and safe treatment option for patients with inadequately controlled moderate-to-severe asthma in Malaysian setting.
布地奈德/福莫特罗(信必可都保)联合治疗作为维持和缓解治疗(SMART)是哮喘管理中的一种新方法。我们研究了其在治疗马来西亚中重度哮喘患者中的“实际疗效”,这些患者尽管使用了吸入性糖皮质激素和长效β2受体激动剂联合治疗,但病情仍控制不佳。在一项回顾性研究中,从一家城市大学医院胸科门诊的病历中确定了22例符合条件的接受SMART治疗的成年患者[平均(范围)年龄:49(36 - 65)岁;FEV1:预计值的41(21 - 74)%],并在三个月时研究了他们的临床结局。另外16例[50(14 - 66)岁;预计值的48(20 - 91)%]病情和治疗情况相似(即信必可都保维持治疗加短效β2受体激动剂作为缓解治疗)但未接受SMART治疗的患者,在相同评估期用作对照。此外,使用标准问卷分别对患者进行访谈,了解他们对SMART方法的满意度和依从性。在SMART组中,急救治疗需求(p<0.001)和FEV1[中位数差异 = 2.5%,p = 0.015;平均差异:90 ml,p = 0.013]显示出显著改善,而在对照组中,仅急救治疗需求有显著改善(p = 0.023)。与对照组相比,SMART组的住院率显著降低(p = 0.039),但急诊治疗方面没有。5例患者要求停用SMART,而其他所有患者都对SMART感到满意、依从,并认为哮喘病情有所改善。吸入布地奈德和福莫特罗的最大日剂量分别为1400微克和31.5微克。我们的初步研究结果表明,在马来西亚的环境中,对于病情控制不佳的中重度哮喘患者,SMART方法可尝试作为一种有效且安全的治疗选择。